Evidence map›Paper›PMID 20679636›Full record

ArticleNeurology2010

Mild cognitive impairment in clinical care: a survey of American Academy of Neurology members.

J S Roberts, J H Karlawish, W R Uhlmann, R C Petersen, R C Green

Registry-linked trialAbstract read
In one paragraph

Article in Neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01434667 (Risk Evaluation and Education for Alzheimer's Disease), which is not on this map. Cited by 33 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01434667 nacompletednot on this map

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

TypeinterventionalSponsorBrigham and Women's HospitalRan2010 to 2014Enrolled146ConditionsMild Cognitive ImpairmentArmsAPOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Memantine for dementia.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project.Health expectations : an international journal of public participation in health care and health policy · 2020
    Observational
  11. Article
  12. Review
  13. Article
  14. The Influence of Psychosocial and Cognitive Factors on Perceived Threat of Alzheimer's Disease.American journal of Alzheimer's disease and other dementias · 2017
    Article
  15. Patient and caregiver reactions to clinical amyloid imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017
    Article
  16. Review
  17. Mild Cognitive Impairment.Continuum (Minneapolis, Minn.) · 2016
    Review
  18. Alzheimer Disease.Continuum (Minneapolis, Minn.) · 2016
    Review
  19. Article
  20. Treatment of Mild Cognitive Impairment.Current treatment options in neurology · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

J S RobertsDepartment of Health Behavior & Health Education, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109, USA. jscottr@umich.edu
J H Karlawish
W R Uhlmann
R C Petersen
R C Green

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI DETRE, JOHN A · 1991 to 2020
$35.1M
Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1M
Risk Evaluation and Education for Alzheimer's Disease (REVEAL IV)R01HG002213 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 1999 to 2012
$7.6M
Characterizing Communicating Genetic Risk Alzheimer'sK24AG027841 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GREEN, ROBERT C. · 2006 to 2010
$914k
NHGRI NIH HHS HG02213NHGRI NIH HHS R01 HG002213NHGRI NIH HHS R01-HG02213NIA NIH HHS K24 AG027841NIA NIH HHS K24-AG027841NIA NIH HHS P30 AG013846NIA NIH HHS P30-AG-10124NIA NIH HHS P30-AG13846NIA NIH HHS P50 AG016574NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904
6 · The paper itself

Abstract

objectiveTo assess how neurologists view mild cognitive impairment (MCI) as a clinical diagnosis and how they treat patients with mild cognitive symptoms.

methodsMembers of the American Academy of Neurology with an aging, dementia, or behavioral neurology practice focus were surveyed by self-administered questionnaire.

resultsSurvey respondents were 420 providers (response rate 48%), and 88% reported at least monthly encounters with patients experiencing mild cognitive symptoms. Most respondents recognize MCI as a clinical diagnosis (90%) and use its diagnostic code for billing purposes (70%). When seeing these patients, most respondents routinely provide counseling on physical (78%) and mental exercise (75%) and communicate about dementia risk (63%); fewer provide information on support services (27%) or a written summary of findings (15%). Most (70%) prescribe cholinesterase inhibitors at least sometimes for this population, with memantine (39%) and other agents (e.g., vitamin E) prescribed less frequently. Respondents endorsed several benefits of a diagnosis of MCI: 1) involving the patient in planning for the future (87%); 2) motivating risk reduction activities (85%); 3) helping with financial planning (72%); and 4) prescribing medications (65%). Some respondents noted drawbacks, including 1) too difficult to diagnose (23%); 2) better described as early Alzheimer disease (21%); and 3) diagnosis can cause unnecessary worry (20%).

conclusionsPatients with mild cognitive symptoms are commonly seen by neurologists, who view MCI as a useful diagnostic category. Information and treatments provided to patients with MCI vary significantly, suggesting a need for practice guidelines and further research on clinical decision-making with this population.

Indexed as

Attitude of Health PersonnelCognition DisordersFemaleHumansMaleMiddle AgedNeurologyPatient Education as TopicPhysiciansPhysician's RoleProfessional PracticeSocieties, MedicalSurveys and QuestionnairesUnited States

Identifiers

PMID20679636
PMCPMC2918467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.